Advertisement

GER and Antacid Medications

  • Jose M. Garza
  • Carlo Di Lorenzo
Chapter

Abstract

Gastric acid secretion is a physiological process essential for food digestion. It is regulated by paracrine, hormonal, and neural pathways. Antacids, surface-protective agents, and antisecretory agents are used for treating gastroesophageal reflux disease (GER). Antacids are helpful for immediate symptomatic relief but are not recommended for chronic use. Histamine-2 receptor antagonists have a role in the management of episodic and mild symptoms, particularly for infrequent GER or reflux-related symptoms. Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications in both children and adults, and their effectiveness for treatment of peptic conditions in the pediatric population has been established. They are well tolerated in both infants and children, but as with any other pharmacologic therapy, PPIs are not exempt of side effects, and risk-benefit should be assessed in individual cases, especially when a chronic use is necessary.

Keywords

Acid Parietal cell Gastrin Antacid Surface-protecting agents Sucralfate Alginates Parietal cell Proton pump inhibitors H2 receptor antagonists H2 blockers 

References

  1. 1.
    Sakai H, Fujii T, Takeguchi N. Proton-potassium (H(+)/K(+)) ATPases: properties and roles in health and diseases. Met Ions Life Sci. 2016;16:459–83.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology. 1993;104(3):834–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Schubert ML, Makhlouf GM. Neural, hormonal, and paracrine regulation of gastrin and acid secretion. Yale J Biol Med. 1992;65(6):553–60. discussion 621-3PubMedPubMedCentralGoogle Scholar
  5. 5.
    Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498–547.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics. 1991;87(2):148–51.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin Pediatr (Phila). 1995;34(2):73–8.CrossRefGoogle Scholar
  8. 8.
    Carroll MW, Jacobson K. Gastroesophageal reflux disease in children and adolescents: when and how to treat. Paediatr Drugs. 2012;14(2):79–89.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tighe M, Afzal NA, Bevan A, Hayen A, Munro A, Beattie RM. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev. 2014;11:CD008550.Google Scholar
  10. 10.
    Corvaglia L, Aceti A, Mariani E, De Giorgi M, Capretti MG, Faldella G. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharmacol Ther. 2011;33(4):466–70.CrossRefPubMedGoogle Scholar
  11. 11.
    Corvaglia L, Spizzichino M, Zama D, Aceti A, Mariani E, Legnani E, et al. Sodium Alginate (Gaviscon(R)) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants. Early Hum Dev. 2011;87(12):775–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Del Buono R, Wenzl TG, Ball G, Keady S, Thomson M. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child. 2005;90(5):460–3.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ummarino D, Miele E, Martinelli M, Scarpato E, Crocetto F, Sciorio E, et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. J Pediatr Gastroenterol Nutr. 2015;60(2):230–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Reimer C, Lodrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909.CrossRefPubMedGoogle Scholar
  15. 15.
    Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon double action liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531–7.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013;11(12):1585–91. quiz e90CrossRefPubMedGoogle Scholar
  18. 18.
    Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med. 1989;86(6A):73–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med. 1990;323(24):1672–80.CrossRefPubMedGoogle Scholar
  20. 20.
    van der Pol R, Langendam M, Benninga M, van Wijk M, Tabbers M. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 2014;168(10):947–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Hyman PE, Garvey TQ 3rd, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr. 1987;110(5):794–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–83.CrossRefPubMedGoogle Scholar
  23. 23.
    Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin N Am. 2013;42(1):93–117.CrossRefGoogle Scholar
  24. 24.
    Jones AW. Perspectives in drug development and clinical pharmacology: the discovery of histamine H1 and H2 antagonists. Clin Pharmacol Drug Dev. 2016;5(1):5–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015;80(2):200–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817–20.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129(1):e40–5.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.PubMedGoogle Scholar
  30. 30.
    Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013;15(2):119–31.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Furuta K, Adachi K, Aimi M, Shimura S, Mikami H, Nishimura N, et al. Effect of timing of proton pump inhibitor administration on acid suppression. Digestion. 2016;93(2):111–20.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41(Suppl 2):S226–42.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tran A, Rey E, Pons G, Pariente-Khayat A, D’Athis P, Sallerin V, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther. 2002;71(5):359–67.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol. 2000;95(11):3101–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lima JJ, Franciosi JP. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics. 2014;15(11):1405–16.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lima JJ, Lang JE, Mougey EB, Blake KB, Gong Y, Holbrook JT, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013;163(3):686–91.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143(2):219–23.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44(1):41–4.Google Scholar
  39. 39.
    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–20. e4CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr. 2013;163(3):692–8. e1-2CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55(1):14–20.PubMedGoogle Scholar
  42. 42.
    Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2014;58(2):226–36.CrossRefPubMedGoogle Scholar
  43. 43.
    van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925–35.CrossRefPubMedGoogle Scholar
  44. 44.
    Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ. Symptomatic reflux disease: the present, the past and the future. Gut. 2014;63(7):1185–93.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945–54.CrossRefPubMedGoogle Scholar
  46. 46.
    Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21(2):149–54.CrossRefPubMedGoogle Scholar
  47. 47.
    Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80–7. 7 e1CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Cucchiara S, Minella R, Iervolino C, Franco MT, Campanozzi A, Franceschi M, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child. 1993;69(6):655–9.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Pfefferkorn MD, Croffie JM, Gupta SK, Molleston JP, Eckert GJ, Corkins MR, et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Pediatr Gastroenterol Nutr. 2006;42(2):160–5.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr. 2000;137(6):800–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 4):S327–35.CrossRefPubMedGoogle Scholar
  52. 52.
    Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 4):S308–18.CrossRefPubMedGoogle Scholar
  53. 53.
    Borrelli O, Rea P, de Bueno MM, et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and lansoprazole for children with gastroesophageal reflux disease. Ital J Pediatr. 2002;28(4):304–9.Google Scholar
  54. 54.
    Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(7):861–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45(5):520–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Tolia V, Youssef NN, Gilger MA, Traxler B, Illueca M. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. J Pediatr Gastroenterol Nutr. 2015;60(Suppl 1):S24–30.CrossRefPubMedGoogle Scholar
  57. 57.
    Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2006;42(4):384–91.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Tsou VM, Baker R, Book L, Hammo AH, Soffer EF, Wang W, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila). 2006;45(8):741–9.CrossRefGoogle Scholar
  59. 59.
    Tolman KG, Taubel J, Warrington S, Chiu YL, Pilmer BL, Pan WJ. Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. Clin Drug Investig. 2006;26(1):21–8.CrossRefPubMedGoogle Scholar
  60. 60.
    McLeay SC, Green B, Treem W, Thyssen A, Mannaert E, Kimko H. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years. Clin Pharmacokinet. 2014;53(10):943–57.CrossRefPubMedGoogle Scholar
  61. 61.
    Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013;57(6):798–807.CrossRefPubMedGoogle Scholar
  62. 62.
    Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Silber S, et al. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. J Pediatr Gastroenterol Nutr. 2014;58(4):510–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Skrzydlo-Radomanska B, Radwan P. Dexlansoprazole – a new – generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191–6.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Kukulka M, Wu J, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2012;54(1):41–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Kukulka M, Nudurupati S, Perez MC. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease. Clin Exp Gastroenterol. 2014;7:461–71.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–4.CrossRefPubMedGoogle Scholar
  67. 67.
    Nand B, Bhagat M. Serious and commonly overlooked side effect of prolonged use of PPI. Am J Med. 2014;127(9):e5.CrossRefPubMedGoogle Scholar
  68. 68.
    Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016;19(9):864–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–19.CrossRefPubMedGoogle Scholar
  70. 70.
    Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Hassall E, Shepherd R, Koletzko S, Radke M, Henderson C, Lundborg P. Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. Aliment Pharmacol Ther. 2012;35(3):368–79.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011;33(7):829–36.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53(2):385–93.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Freedberg DE, Lamouse-Smith ES, Lightdale JR, Jin Z, Yang YX, Abrams JA. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study. Clin Infect Dis. 2015;61(6):912–7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Stark CM, Nylund CM. Side effects and complications of proton pump inhibitors: a pediatric perspective. J Pediatr. 2016;168:16–22.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150(3):262–7. 7 e1CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Children’s Center for Digestive HealthcareAtlantaUSA
  2. 2.Neurogastroenterology and MotilityChildren’s Healthcare of AtlantaAtlantaUSA
  3. 3.PediatricsThe Ohio State UniversityColumbusUSA
  4. 4.Division of Pediatric GastroenterologyNationwide Children’s HospitalColumbusUSA

Personalised recommendations